UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 7, 2023
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code 781 -848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | |||||
Emerging Growth Company | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | |||||
Item 2.02 Results of Operations and Financial Condition.
On February 7, 2023, Haemonetics Corporation issued a press release announcing financial results for the third quarter and nine months ended December 31, 2022. A copy of the press release is furnished with this report as Exhibit 99.1.
The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
Press Release of Haemonetics Corporation dated February 7, 2023 announcing financial results for the third quarter and nine months ended December 31, 2022. | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
Date: February 7, 2023 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
| Exhibit 99.1 | |||||||||||
| Investor Contacts | Media Contact | ||||||||||
| Olga Guyette, Sr. Director-Investor Relations & Treasury | Josh Gitelson, Director-Communications | ||||||||||
| (781) 356-9763 | (781) 356-9776 | ||||||||||
| olga.guyette@haemonetics.com | josh.gitelson@haemonetics.com | ||||||||||
| David Trenk, Manager-Investor Relations | |||||||||||
| (203) 733-4987 | |||||||||||
| david.trenk@haemonetics.com | |||||||||||
Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2023 Results; Updates Fiscal 2023 Guidance
Boston, MA, February 7, 2023 - Haemonetics Corporation (NYSE: HAE) reported financial results for its third quarter and year-to-date fiscal 2023, which ended December 31, 2022:
| 3rd Quarter 2023 | YTD 2023 | |||||||||||||
| n | Revenue, increase | $305 million, 18% | $864 million, 19% | |||||||||||
| n | Organic1 revenue increase | 21% | 22% | |||||||||||
| n | Earnings per diluted share | $0.64 | $1.67 | |||||||||||
| n | Adjusted earnings per diluted share | $0.85 | $2.26 | |||||||||||
| n | Cash flow from operating activities | $64 million | $193 million | |||||||||||
| n | Free cash flow before restructuring & restructuring related costs | $53 million | $119 million | |||||||||||
1 Excludes the impact of currency fluctuation and strategic exits of product lines. | ||||||||||||||
Chris Simon, Haemonetics’ CEO, stated: "Our strong performance continued in the third quarter despite the challenging macroeconomic environment. We are fueling our momentum and using it to invest in our Long-Range Plan, expanding our capital capacity and creating new opportunities to accelerate transformational growth and margin expansion."
GAAP RESULTS
Third quarter fiscal 2023 revenue was $305.3 million, up 17.5% compared with the third quarter of fiscal 2022. Business unit revenue and growth rates compared with the prior year period were as follows:
| ($ millions) | 3rd Quarter 2023 Reported | |||||||
| Plasma | $135.5 | 40.4% | ||||||
| Blood Center | $73.4 | (3.1%) | ||||||
| Hospital | $91.5 | 11.3% | ||||||
| Net business unit revenue | $300.4 | 18.1% | ||||||
| Service | 4.9 | (8.0%) | ||||||
| Total net revenue | $305.3 | 17.5% | ||||||
1
Gross margin was 52.0% in the third quarter of fiscal 2023 compared with 53.3% in the third quarter of fiscal 2022. The primary drivers of the decrease in the gross margin percentage were inflationary pressures in our global manufacturing and supply chain and increased depreciation expense, partially offset by price, volume and productivity savings from the Operational Excellence Program. Operating expenses were $115.4 million in the third quarter of fiscal 2023 compared with $102.9 million in the third quarter of fiscal 2022. The increase in operating expenses was primarily driven by higher performance-based compensation, an increase in freight volumes and costs and continuous growth investments, partially offset by lower deal amortization. The Company had operating income of $43.3 million and a 14.2% operating margin in the third quarter of fiscal 2023, compared with operating income of $35.7 million and an operating margin of 13.7% in the third quarter of fiscal 2022. The income tax rates were 22.0% and 26.0% in the third quarters of fiscal 2023 and fiscal 2022, respectively. Third quarter fiscal 2023 net income and earnings per diluted share were $32.9 million and $0.64, respectively, compared with net income and earnings per diluted share of $23.2 million and $0.45, respectively, in the third quarter of fiscal 2022.
ADJUSTED RESULTS
Organic revenue for the third quarter of fiscal 2023 was up 21.2% compared with the same period of fiscal 2022. Business unit organic revenue growth rates compared with the prior year period were as follows:
| 3rd Quarter 2023 Organic | |||||
| Plasma | 42.3% | ||||
| Blood Center | 3.1% | ||||
| Hospital | 14.4% | ||||
| Net business unit revenue | 27.1% | ||||
| Service | (1.2%) | ||||
| Total net revenue | 21.2% | ||||
Third quarter fiscal 2023 adjusted gross margin was 52.5%, down 240 basis points compared with the prior year period. The primary drivers of the decrease were inflationary pressures in our global manufacturing and supply chain and increased depreciation expense, partially offset by price, volume and productivity savings from the Operational Excellence Program.
Adjusted operating expenses in the third quarter of fiscal 2023 were $101.4 million, up $17.6 million, or 21.0%, compared with the prior year period. The increase in adjusted operating expenses was primarily driven by higher performance-based compensation, an increase in freight volumes and costs and continuous growth investments. Adjusted operating income for the third quarter of fiscal 2023 was $59.0 million, up $0.2 million or 0.3%, and adjusted operating margin was 19.3%, down 330 basis points when compared with the same period of fiscal 2022. The adjusted income tax rates were 24.8% and 21.4% in the third quarters of fiscal 2023 and fiscal 2022, respectively.
Third quarter fiscal 2023 adjusted net income was $43.6 million, up $0.7 million, or 1.5%, and adjusted earnings per diluted share was $0.85, up 1.2%, when compared with the same period of fiscal 2022.
2
RESTRUCTURING AND RESTRUCTURING RELATED COSTS, DEAL AMORTIZATION AND CERTAIN OTHER COSTS
The Company incurred restructuring and restructuring related costs of $4.1 million in the third quarter of fiscal 2023 compared with $5.7 million in the third quarter of fiscal 2022 and deal amortization expenses of $8.1 million in the third quarter of fiscal 2023 compared with $12.2 million in the third quarter of fiscal 2022.
In addition, during the third quarters of both fiscal 2023 and fiscal 2022, the Company incurred $2.5 million of costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation.
BALANCE SHEET AND CASH FLOW
Cash on hand at December 31, 2022 was $224.0 million, a decrease of $35.5 million since April 2, 2022. The Company repurchased $75.0 million of its common stock pursuant to an accelerated share repurchase agreement entered into during the second fiscal quarter. Additionally, the Company paid $32.3 million of earnout payments related to acquisitions and made investments in Vivasure Medical LTD totaling €30 million.
Cash flow from operating activities was $64.4 million and free cash flow before restructuring and restructuring related costs was $52.8 million during the third quarter of fiscal 2023, compared with $62.4 million and $44.7 million, respectively, in the same period of fiscal 2022.
SHARE REPURCHASE PROGRAM
As part of its previously announced $300 million share repurchase program, the Company repurchased 997,406 shares of its common shares for $75.0 million via an accelerated share repurchase agreement with Citibank, N.A. The initial delivery of 786,164 shares occurred at the end of the second quarter with a final delivery of 211,242 shares completed in the third quarter. The remaining authorized amount of share repurchase activity through August 2025 is $225 million.
FISCAL 2023 GUIDANCE
The Company updated its previous fiscal 2023 GAAP total revenue growth guidance from 12 - 15% to 15 - 17% and its fiscal 2023 organic revenue growth guidance as follows:
Previous Organic1 Guidance | Current Organic1 Guidance | ||||||||||
| Total revenue | 15 - 18% | 18 - 20% | |||||||||
| Plasma revenue | 30 - 35% | 35 - 40% | |||||||||
| Blood Center revenue | (2 - 5%) | (2 - 4%) | |||||||||
| Hospital revenue | 19 - 22% | ~19% | |||||||||
1Excludes the impact of currency fluctuation and strategic exits of product lines. Reconciliations of reported to organic revenue are provided in the schedules accompanying this release and in the analytical tables referenced below. | |||||||||||
3
Additionally, the Company reaffirmed its adjusted operating margin guidance and updated its adjusted earnings per diluted share guidance and free cash flow before restructuring and restructuring related costs guidance as follows:
| Previous Guidance | Current Guidance | ||||||||||
Adjusted operating margin | 18 - 19% | 18 - 19% | |||||||||
Adjusted earnings per diluted share | $2.70 - $3.00 | $2.90 - $3.00 | |||||||||
Free cash flow, before restructuring & restructuring related costs | $150M - $180M | $160M - $180M | |||||||||
WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS
The Company will host a conference call with investors and analysts to discuss third quarter fiscal 2023 results on Tuesday, February 7, 2023 at 8:00 a.m. ET. The call can be accessed via teleconference at https://register.vevent.com/register/BIe8538d46f9014830b1de5ab9e697b6ec. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/mmc/p/pt8ugsbv
The Company is posting this press release to its investor relations website, in addition to supplemental analytical tables that will be referenced on the webcast. These supplemental analytical tables can be accessed at the following direct link: https://haemonetics.gcs-web.com/static-files/8ab8cd45-cbd4-4be8-b245-99ad01e6e40e
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products and plans or objectives related to the Operational Excellence Program; (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the share repurchase program; (iii) the impact of the COVID-19 pandemic and associated inflationary pressures on the Company’s operations, availability and demand for its products, and future financial performance, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking
4
statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the impact of the COVID-19 pandemic, including its scope and duration (including the extent of future surges, variants and the efficacy of vaccinations), government actions and restrictive measures implemented in response and associated economic disruptions, including inflationary pressures and higher freight costs in our global supply chain; availability and demand for the Company’s products; the Company’s ability to implement as planned and realize estimated cost savings from the Operational Excellence Program; the Company’s ability to execute business continuity plans; risks arising from planned or completed acquisitions or divestitures by the Company, including any failure to realize the anticipated strategic benefits and opportunities of the transaction; the impact of share repurchases on the Company’s stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program’s effectiveness; technological advances in the medical field and standards for transfusion medicine and the Company’s ability to successfully offer products that incorporate such advances and standards; product quality; market acceptance; regulatory uncertainties, including in the receipt or timing of regulatory approvals; the effect of economic and political conditions; the impact of competitive products and pricing; blood product reimbursement policies and practices; and the effect of industry consolidation as seen in the plasma market. These and other factors are identified and described in more detail in the Company’s periodic reports and other filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company does not undertake to update these forward-looking statements.
MANAGEMENT’S USE OF NON-GAAP MEASURES
This press release contains financial measures that are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations and provide a baseline for analyzing trends in the Company’s underlying businesses. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.
When used in this release, organic revenue growth excludes the impact of currency fluctuation and strategic exits of product lines. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted net income and adjusted earnings per diluted share exclude restructuring and restructuring related costs, deal amortization expenses, asset
5
impairments, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, integration and transaction costs, gains and losses on dispositions, certain tax settlements and unusual or infrequent and material litigation-related charges. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. Free cash flow before restructuring and restructuring related costs is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.
A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com. The Company does not provide a quantitative reconciliation of its forward-looking organic revenue growth guidance by business unit to the comparable GAAP measure because forecasting the impact of foreign currency fluctuations by business unit is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. Additionally, the Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow before restructuring and restructuring related costs guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs and impairment charges, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company’s financial performance.
6
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of Income for the Third Quarter of FY23 and FY22 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 12/31/2022 | 1/1/2022 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 305,301 | $ | 259,769 | 17.5% | |||||||||||||||
| Gross profit | 158,707 | 138,565 | 14.5% | |||||||||||||||||
| R&D | 12,689 | 10,037 | 26.4% | |||||||||||||||||
| S,G&A | 94,661 | 80,726 | 17.3% | |||||||||||||||||
| Amortization of intangible assets | 8,078 | 12,151 | (33.5)% | |||||||||||||||||
| Operating expenses | 115,428 | 102,914 | 12.2% | |||||||||||||||||
| Operating income | 43,279 | 35,651 | 21.4% | |||||||||||||||||
| Interest and other expense, net | (1,055) | (4,263) | (75.3)% | |||||||||||||||||
| Income before taxes | 42,224 | 31,388 | 34.5% | |||||||||||||||||
| Tax expense | 9,280 | 8,156 | 13.8% | |||||||||||||||||
| Net income | $ | 32,944 | $ | 23,232 | 41.8% | |||||||||||||||
| Net income per common share assuming dilution | $ | 0.64 | $ | 0.45 | 42.2% | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 50,509 | 51,094 | ||||||||||||||||||
| Diluted | 51,219 | 51,344 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 52.0 | % | 53.3 | % | (1.3)% | |||||||||||||||
| R&D | 4.2 | % | 3.9 | % | 0.3% | |||||||||||||||
| S,G&A | 31.0 | % | 31.1 | % | (0.1)% | |||||||||||||||
| Operating income | 14.2 | % | 13.7 | % | 0.5% | |||||||||||||||
| Income before taxes | 13.8 | % | 12.1 | % | 1.7% | |||||||||||||||
| Net income | 10.8 | % | 8.9 | % | 1.9% | |||||||||||||||
7
| Haemonetics Corporation Financial Summary | ||||||||||||||||||||
| Condensed Consolidated Statements of Income for the Year-to-Date FY23 and FY22 | ||||||||||||||||||||
| (Data in thousands, except per share data) | ||||||||||||||||||||
| 12/31/2022 | 1/1/2022 | % Inc/(Dec) | ||||||||||||||||||
| vs Prior Year | ||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||
| Net revenues | $ | 864,244 | $ | 728,194 | 18.7% | |||||||||||||||
| Gross profit | 458,848 | 369,191 | 24.3% | |||||||||||||||||
| R&D | 34,487 | 33,591 | 2.7% | |||||||||||||||||
| S,G&A | 279,299 | 247,722 | 12.7% | |||||||||||||||||
| Amortization of intangible assets | 24,666 | 35,930 | (31.3)% | |||||||||||||||||
| Gains on divestiture | (382) | (9,603) | (96.0)% | |||||||||||||||||
| Operating expenses | 338,070 | 307,640 | 9.9% | |||||||||||||||||
| Operating income | 120,778 | 61,551 | 96.2% | |||||||||||||||||
| Interest and other expense, net | (12,001) | (13,249) | (9.4)% | |||||||||||||||||
| Income before taxes | 108,777 | 48,302 | 125.2% | |||||||||||||||||
| Tax expense | 22,759 | 14,668 | 55.2% | |||||||||||||||||
| Net income | $ | 86,018 | $ | 33,634 | 155.7% | |||||||||||||||
| Net income per common share assuming dilution | $ | 1.67 | $ | 0.65 | 156.9% | |||||||||||||||
| Weighted average number of shares: | ||||||||||||||||||||
| Basic | 50,896 | 51,024 | ||||||||||||||||||
| Diluted | 51,487 | 51,356 | ||||||||||||||||||
| Profit Margins: | Inc/(Dec) vs prior year profit margin % | |||||||||||||||||||
| Gross profit | 53.1 | % | 50.7 | % | 2.4% | |||||||||||||||
| R&D | 4.0 | % | 4.6 | % | (0.6)% | |||||||||||||||
| S,G&A | 32.3 | % | 34.0 | % | (1.7)% | |||||||||||||||
| Operating income | 14.0 | % | 8.5 | % | 5.5% | |||||||||||||||
| Income before taxes | 12.6 | % | 6.6 | % | 6.0% | |||||||||||||||
| Net income | 10.0 | % | 4.6 | % | 5.4% | |||||||||||||||
8
| Revenue Analysis for the Third Quarter of FY23 and FY22 | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||
| 12/31/2022 | 1/1/2022 | Reported growth | Currency impact | Other Strategic Exits(1) | Organic growth | |||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 135,461 | $ | 96,460 | 40.4 | % | (0.8) | % | (1.1) | % | 42.3 | % | ||||||||||||||||||||||||||
| Blood Center | 73,362 | 75,692 | (3.1) | % | (6.2) | % | — | % | 3.1 | % | ||||||||||||||||||||||||||||
Hospital(2) | 91,560 | 82,273 | 11.3 | % | (3.1) | % | — | % | 14.4 | % | ||||||||||||||||||||||||||||
| Net business unit revenues | $ | 300,383 | $ | 254,425 | 18.1 | % | (3.2) | % | (0.4) | % | 21.7 | % | ||||||||||||||||||||||||||
| Service | 4,918 | 5,344 | (8.0) | % | (6.8) | % | — | % | (1.2) | % | ||||||||||||||||||||||||||||
| Total net revenues | $ | 305,301 | $ | 259,769 | 17.5 | % | (3.3) | % | (0.4) | % | 21.2 | % | ||||||||||||||||||||||||||
(1) Reflects adjustments to both fiscal 2023 and 2022 Plasma revenue due to certain strategic exits within the liquid solutions business. (2) Hospital revenue includes Hemostasis Management revenue of $34.9 million and $33.5 million for the three months ended December 31, 2022 and January 1, 2022, respectively. Hemostasis Management revenue increased 4.2% in the third quarter of fiscal 2023 as compared with the same period of fiscal 2022. Hemostasis Management revenue increased 7.3%, on an organic basis, in the third quarter of fiscal 2023 as compared with the same period of fiscal 2022. Hospital revenue also includes Vascular Closure revenue of $32.2 million and $24.3 million for the three months ended December 31, 2022 and January 1, 2022, respectively. Vascular Closure revenue increased on a reported and organic basis 32.6% in the third quarter of fiscal 2023 as compared with the same period of fiscal 2022. | ||||||||||||||||||||||||||||||||||||||
9
| Revenue Analysis for the Year-to-Date FY23 and FY22 | ||||||||||||||||||||||||||||||||||||||
| (Data in thousands) | ||||||||||||||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||
| 12/31/2022 | 1/1/2022 | Reported growth | Currency impact | Other Strategic Exits(1) | Organic growth | |||||||||||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||||||||||||||||
| Revenues by business unit | ||||||||||||||||||||||||||||||||||||||
| Plasma | $ | 365,735 | $ | 250,244 | 46.2 | % | (0.9) | % | (0.9) | % | 48.0 | % | ||||||||||||||||||||||||||
| Blood Center | 212,739 | 225,379 | (5.6) | % | (4.5) | % | — | % | (1.1) | % | ||||||||||||||||||||||||||||
Hospital(2) | 270,909 | 237,074 | 14.3 | % | (2.7) | % | — | % | 17.0 | % | ||||||||||||||||||||||||||||
| Net business unit revenues | $ | 849,383 | $ | 712,697 | 19.2 | % | (2.8) | % | (0.2) | % | 22.2 | % | ||||||||||||||||||||||||||
| Service | 14,861 | 15,497 | (4.1) | % | (5.8) | % | — | % | 1.7 | % | ||||||||||||||||||||||||||||
| Total net revenues | $ | 864,244 | $ | 728,194 | 18.7 | % | (2.8) | % | (0.3) | % | 21.8 | % | ||||||||||||||||||||||||||
(1) Reflects adjustments to both fiscal 2023 and 2022 Plasma revenue due to certain strategic exits within the liquid solutions business. (2) Hospital revenue includes Hemostasis Management revenue of $102.7 million and $97.2 million for the nine months ended December 31, 2022 and January 1, 2022, respectively. Hemostasis Management revenue increased 5.7% in the first nine months of fiscal 2023 as compared with the same period of fiscal 2022. Hemostasis Management revenue increased 8.1%, on an organic basis, in the first nine months of fiscal 2023 as compared with the same period of fiscal 2022. Hospital revenue also includes Vascular Closure revenue of $91.3 million and $66.8 million for the nine months ended December 31, 2022 and January 1, 2022, respectively. Vascular Closure revenue increased on a reported and organic basis 36.6% in the first nine months of fiscal 2023 as compared with the same period of fiscal 2022. | ||||||||||||||||||||||||||||||||||||||
10
| Condensed Consolidated Balance Sheets | |||||||||||||||||
| (Data in thousands) | |||||||||||||||||
| As of | |||||||||||||||||
| 12/31/2022 | 4/2/2022 | ||||||||||||||||
| (unaudited) | |||||||||||||||||
| Assets | |||||||||||||||||
| Cash and cash equivalents | $ | 224,002 | $ | 259,496 | |||||||||||||
| Accounts receivable, net | 181,100 | 159,376 | |||||||||||||||
| Inventories, net | 255,756 | 293,027 | |||||||||||||||
| Other current assets | 45,451 | 44,132 | |||||||||||||||
| Total current assets | 706,309 | 756,031 | |||||||||||||||
| Property, plant & equipment, net | 313,138 | 258,482 | |||||||||||||||
| Intangible assets, net | 284,383 | 310,261 | |||||||||||||||
| Goodwill | 466,112 | 467,287 | |||||||||||||||
| Other assets | 108,124 | 67,673 | |||||||||||||||
| Total assets | $ | 1,878,066 | $ | 1,859,734 | |||||||||||||
| Liabilities & Stockholders' Equity | |||||||||||||||||
| Short-term debt & current maturities | $ | 9,949 | $ | 214,148 | |||||||||||||
| Other current liabilities | 216,940 | 228,118 | |||||||||||||||
| Total current liabilities | 226,889 | 442,266 | |||||||||||||||
| Long-term debt | 756,826 | 559,441 | |||||||||||||||
| Other long-term liabilities | 118,372 | 108,603 | |||||||||||||||
| Stockholders' equity | 775,979 | 749,424 | |||||||||||||||
| Total liabilities & stockholders' equity | $ | 1,878,066 | $ | 1,859,734 | |||||||||||||
11
| Condensed Consolidated Statements of Cash Flows | |||||||||||
| (Data in thousands) | |||||||||||
| Nine Months Ended | |||||||||||
| 12/31/2022 | 1/1/2022 | ||||||||||
| (unaudited) | |||||||||||
| Cash Flows from Operating Activities: | |||||||||||
| Net income | $ | 86,018 | $ | 33,634 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 69,453 | 72,934 | |||||||||
| Contingent consideration | (504) | 10,272 | |||||||||
| Share-based compensation expense | 18,525 | 19,262 | |||||||||
| Impairment of assets | 94 | 5,144 | |||||||||
| Amortization of deferred financing costs | 1,098 | 2,608 | |||||||||
| Provision (benefit) for losses on inventory | 483 | (280) | |||||||||
| Gains on divestiture | (382) | (9,603) | |||||||||
| Change in other non-cash operating activities | 1,046 | 8,397 | |||||||||
| Change in accounts receivable, net | (24,370) | (28,736) | |||||||||
| Change in inventories, net | 34,506 | 11,589 | |||||||||
| Change in other working capital | 7,480 | (21,008) | |||||||||
| Net cash provided by operating activities | 193,447 | 104,213 | |||||||||
| Cash Flows from Investing Activities: | |||||||||||
| Capital expenditures | (98,272) | (61,394) | |||||||||
| Acquisition | (2,850) | (2,500) | |||||||||
| Proceeds from divestiture | 850 | 10,642 | |||||||||
| Proceeds from sale of property, plant and equipment | 7,695 | 1,419 | |||||||||
| Other investments | (33,205) | — | |||||||||
| Net cash used in investing activities | (125,782) | (51,833) | |||||||||
| Cash Flows from Financing Activities: | |||||||||||
| Borrowings, net of repayments | (7,875) | (13,125) | |||||||||
| Debt issuance costs | (1,118) | — | |||||||||
| Share repurchases | (75,000) | — | |||||||||
| Contingent consideration payments | (21,593) | — | |||||||||
| Proceeds from employee stock programs | 6,857 | 6,133 | |||||||||
| Other | (32) | 8 | |||||||||
| Net cash used in financing activities | (98,761) | (6,984) | |||||||||
| Effect of exchange rates on cash and cash equivalents | (4,398) | (824) | |||||||||
| Net Change in Cash and Cash Equivalents | (35,494) | 44,572 | |||||||||
| Cash and Cash Equivalents at Beginning of the Period | 259,496 | 192,305 | |||||||||
| Cash and Cash Equivalents at End of Period | $ | 224,002 | $ | 236,877 | |||||||
| Free Cash Flow Reconciliation: | |||||||||||
| Cash provided by operating activities | $ | 193,447 | $ | 104,213 | |||||||
| Capital expenditures, net of proceeds from sale of property, plant and equipment | (90,577) | (59,975) | |||||||||
| Free cash flow after restructuring and restructuring related costs | 102,870 | 44,238 | |||||||||
| Restructuring and restructuring related costs | 20,386 | 39,956 | |||||||||
| Tax benefit on restructuring and restructuring related costs | (4,241) | (8,353) | |||||||||
| Free cash flow before restructuring and restructuring related costs | $ | 119,015 | $ | 75,841 | |||||||
12
| Reconciliation of Adjusted Measures for the Third Quarter of FY23 and FY22 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Three Months Ended | |||||||||||
| 12/31/2022 | 1/1/2022 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 158,707 | $ | 138,565 | |||||||
| Restructuring and restructuring related costs | 1,798 | 3,226 | |||||||||
| Impairment of assets and PCS2 related charges | (122) | 832 | |||||||||
MDR and IVDR costs(1) | 11 | — | |||||||||
| Adjusted gross profit | $ | 160,394 | $ | 142,623 | |||||||
| GAAP operating expenses | $ | 115,428 | $ | 102,914 | |||||||
| Deal amortization | (8,078) | (12,151) | |||||||||
| Integration and transaction costs | (287) | (1,860) | |||||||||
MDR and IVDR costs(1) | (2,472) | (2,453) | |||||||||
| Restructuring and restructuring related costs | (2,327) | (2,456) | |||||||||
| Litigation-related charges | (757) | (138) | |||||||||
| Impairment of assets and PCS2 related charges | (120) | (65) | |||||||||
| Adjusted operating expenses | $ | 101,387 | $ | 83,791 | |||||||
| GAAP operating income | $ | 43,279 | $ | 35,651 | |||||||
| Deal amortization | 8,078 | 12,151 | |||||||||
| Integration and transaction costs | 287 | 1,860 | |||||||||
| Restructuring and restructuring related costs | 4,125 | 5,682 | |||||||||
| Impairment of assets and PCS2 related charges | (2) | 897 | |||||||||
MDR and IVDR costs(1) | 2,483 | 2,453 | |||||||||
| Litigation-related charges | 757 | 138 | |||||||||
| Adjusted operating income | $ | 59,007 | $ | 58,832 | |||||||
| GAAP net income | $ | 32,944 | $ | 23,232 | |||||||
| Deal amortization | 8,078 | 12,151 | |||||||||
| Integration and transaction costs | 287 | 1,860 | |||||||||
| Restructuring and restructuring related costs | 4,125 | 5,682 | |||||||||
| Impairment of assets and PCS2 related charges | (2) | 897 | |||||||||
MDR and IVDR costs(1) | 2,483 | 2,453 | |||||||||
| Litigation-related charges | 757 | 138 | |||||||||
| Tax impact associated with adjustments | (5,112) | (3,512) | |||||||||
| Adjusted net income | $ | 43,560 | $ | 42,901 | |||||||
| GAAP net income per common share | $ | 0.64 | $ | 0.45 | |||||||
| Adjusted items after tax per common share assuming dilution | 0.21 | 0.39 | |||||||||
| Adjusted net income per common share assuming dilution | $ | 0.85 | $ | 0.84 | |||||||
(1)Refers to European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) related costs. | |||||||||||
13
| Reconciliation of Adjusted Measures for Year-to-Date FY23 and FY22 | |||||||||||
| (Data in thousands except per share data) | |||||||||||
| Nine Months Ended | |||||||||||
| 12/31/2022 | 1/1/2022 | ||||||||||
| (unaudited) | |||||||||||
| GAAP gross profit | $ | 458,848 | $ | 369,191 | |||||||
| Restructuring and restructuring related costs | 5,935 | 14,738 | |||||||||
| Integration and transaction costs | — | 5,295 | |||||||||
| Impairment of assets and PCS2 related charges | (470) | 4,547 | |||||||||
MDR and IVDR costs(1) | 101 | — | |||||||||
| Adjusted gross profit | $ | 464,414 | $ | 393,771 | |||||||
| GAAP operating expenses | $ | 338,070 | $ | 307,640 | |||||||
| Deal amortization | (24,666) | (35,930) | |||||||||
| Integration and transaction costs | 425 | (13,923) | |||||||||
MDR and IVDR costs(1) | (8,074) | (7,171) | |||||||||
| Restructuring and restructuring related costs | (4,862) | (5,512) | |||||||||
| Litigation-related charges | (1,151) | (1,221) | |||||||||
| Impairment of assets and PCS2 related charges | (201) | (243) | |||||||||
| Gains on divestiture | 382 | 9,603 | |||||||||
| Adjusted operating expenses | $ | 299,923 | $ | 253,243 | |||||||
| GAAP operating income | $ | 120,778 | $ | 61,551 | |||||||
| Deal amortization | 24,666 | 35,930 | |||||||||
| Integration and transaction costs | (425) | 19,218 | |||||||||
| Restructuring and restructuring related costs | 10,797 | 20,250 | |||||||||
| Impairment of assets and PCS2 related charges | (269) | 4,790 | |||||||||
MDR and IVDR costs(1) | 8,175 | 7,171 | |||||||||
| Litigation-related charges | 1,151 | 1,221 | |||||||||
| Gains on divestiture | (382) | (9,603) | |||||||||
| Adjusted operating income | $ | 164,491 | $ | 140,528 | |||||||
| GAAP net income | $ | 86,018 | $ | 33,634 | |||||||
| Deal amortization | 24,666 | 35,930 | |||||||||
| Integration and transaction costs | (425) | 19,218 | |||||||||
| Restructuring and restructuring related costs | 10,797 | 20,250 | |||||||||
| Impairment of assets and PCS2 related charges | (269) | 4,790 | |||||||||
MDR and IVDR costs(1) | 8,175 | 7,171 | |||||||||
| Litigation-related charges | 1,151 | 1,221 | |||||||||
| Gains on divestiture | (382) | (9,603) | |||||||||
| Tax impact associated with adjustments | (13,262) | (13,578) | |||||||||
| Adjusted net income | $ | 116,469 | $ | 99,033 | |||||||
| GAAP net income per common share | $ | 1.67 | $ | 0.65 | |||||||
| Adjusted items after tax per common share assuming dilution | 0.59 | 1.28 | |||||||||
| Adjusted net income per common share assuming dilution | $ | 2.26 | $ | 1.93 | |||||||
(1)Refers to European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”) related costs. | |||||||||||
14
| Projected Fiscal 2023 GAAP and Organic Revenue Growth Rates | |||||
| FY 2023 | |||||
| GAAP Revenue Growth | 15 - 17% | ||||
| Currency impact | 3% | ||||
Organic Revenue Growth(1) | 18 - 20% | ||||
(1) Reflects adjustments to Plasma revenue due to certain strategic exits within the liquid solution business that are projected to be less than 1%. | |||||
15